Meropenem Acs Dobfar

Meropenem, the active ingredient in Meropenem Acs Dobfar, is a carbapenem antibiotic presented as a sterile powder for intravenous infusion use. It treats a range of serious bacterial infections in hospitalized patients, including intra‑abdominal, urinary, respiratory, central nervous system and bloodstream infections.

GNH USA supplies Meropenem Acs Dobfar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Meropenem is a broad‑spectrum carbapenem used for severe bacterial infections across several organ systems.

- Complicated intra‑abdominal infections: provides rapid bacterial eradication in severe abdominal sepsis. - Complicated urinary tract infections: eliminates resistant uropathogens causing pyelonephritis and cystitis. - Nosocomial pneumonia: treats hospital‑acquired and ventilator‑associated lung infections. - Meningitis: penetrates the cerebrospinal fluid to clear central nervous system infections. - Sepsis: offers bactericidal activity in systemic bloodstream infections. - Skin and soft tissue infections: resolves deep tissue and necrotizing infections caused by Gram‑negative organisms.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Vomiting: occasional emesis during or after infusion. - Diarrhea: loose stools, sometimes watery. - Headache: transient cranial discomfort. - Rash: mild erythematous skin eruption. - Phlebitis at infusion site: local irritation or inflammation.

Serious or Rare Side Effects: - Seizures: especially in patients with renal dysfunction or high doses. - Clostridioides difficile colitis: severe diarrhea due to gut flora disruption. - Anaphylaxis: acute hypersensitivity reaction with respiratory or cardiovascular compromise. - Renal toxicity: worsening kidney function in susceptible individuals. - Hepatic enzyme elevation: transient increase in liver transaminases. - Neutropenia: marked reduction in white blood cell count.

Careful assessment and monitoring are required before and during therapy.

- Renal function: adjust dose in patients with impaired clearance. - Allergy: avoid in individuals with known carbapenem hypersensitivity. - Pregnancy: use only when the potential benefit justifies the risk to the fetus. - Concomitant valproic acid: monitor for reduced antiepileptic levels. - Drug interactions: review all concurrent medications for possible effects. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Meropenem may interact with several agents, requiring clinical vigilance.

Major Interactions (Avoid): - Valproic acid: carbapenems can markedly reduce serum valproate concentrations, risking seizure breakthrough. - Cytotoxic chemotherapy: increased risk of myelosuppression when combined.

Moderate Interactions (Monitor Closely): - Probenecid: may decrease renal excretion of meropenem, raising plasma levels. - Loop diuretics: potential for enhanced nephrotoxicity, especially in renal impairment. - Warfarin: occasional alteration of INR, requiring coagulation monitoring.